Učitavanje...
Racial Disparities in the Utilization of Novel Agents for Front-line Treatment of Multiple Myeloma
BACKGROUND: Treatment with novel agents has become the standard-of-care for newly diagnosed multiple myeloma, but members of racial and ethnic minority groups receive these agents at a lower rate than their peers. Researchers have largely attributed this finding to the higher costs of these drugs in...
Spremljeno u:
| Izdano u: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8247682/ https://ncbi.nlm.nih.gov/pubmed/32522440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.04.018 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|